Status:
RECRUITING
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
Lead Sponsor:
Hôpital Européen Marseille
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
In the last 40 years of HIV history, we have managed to attain most of our therapeutic objectives, namely virological suppression of most patients and sufficient immune reconstitution. Still, immune a...
Eligibility Criteria
Inclusion
- PLWH at a the stable phase of their disease (absence of disease outbreak and absence of treatment modification in the 3 months preceding inclusion),
- Subject with ongoing HIV follow-up on an outpatient basis (outpatient or day hospital consultation) in the participating center, and having virological suppression at the threshold of 50 copies / mL for at least 1 year (blips \< 200 copies / mL tolerated during this period)
- CD4 + T cell nadir\> 200 / mm3
- Having given free and informed written consent
- Being affiliated with or benefiting from a social security scheme.
Exclusion
- Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two month before stool sampling.
- Subject only coming for full impatient follow-up
Key Trial Info
Start Date :
April 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05303337
Start Date
April 11 2022
End Date
March 1 2026
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Européen Marseille
Marseille, France, 13003